ENMD-2076
ENMD-2076 is a multi-targeted kinase inhibitor with potent activity against Aurora A, Flt3, VEGFR2/3, FGFR1/2, Src, and PDGFRα. It has demonstrated antitumor efficacy in preclinical models, supporting its investigation in oncology research for cancers dependent on these signaling pathways, including breast and ovarian malignancies.
Product Specifications
CAS Number
934353-76-1
Product Name Alternative
Src, RET, PDGFR, VEGFR, VEGFR3/FLT4, Vascular endothelial growth factor receptor, ENMD 2076, ENMD2076, ENMD-2076, Fms like tyrosine kinase 3, Fibroblast growth factor receptor, FGFR, FLT3, Inhibitor, inhibit, Platelet-derived growth factor receptor, CD135, Cluster of differentiation antigen 135, cRET, AuroraKinase, Aurora Kinase, Aurora A, Apoptosis
Field of Research
Cardiovascular Research, Cell Biology, Epigenetics & Chromatin, Signal Transduction
Purity
≥95% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:3.3 mg/mL (8.79 mM) ; DMSO:97 mg/mL (258.34 mM) ; H2O:1 mg/mL (2.66 mM) ; Ethanol:< 1 mg/mL (insoluble or slightly soluble)
Smiles
CN1CCN (CC1) c1cc (Nc2cc (C) [nH]n2) nc (\C=C\c2ccccc2) n1
Molecular Formula
C21H25N7
Molecular Weight
375.47
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR10377385 96 Well
Porcine Armadillo repeat protein deleted in velo cardio facial syndrome (ARVCF) ELISA kit
Sign In for Pricing
View Details 